The Scientific Advisory Board is regularly consulted to help define vaccine strategies and solutions. The SAB also advises on Intravacc’s research strategy and approaches to optimize therapy effectiveness and added value.
Chaired by Intravacc’s Chief Scientific Officer Virgil Schijns, the SAB further comprises scientific leaders in the fields of vaccinology, infectious diseases and oncology.